Medicine and Dentistry
Pioglitazone
100%
Therapeutic Procedure
54%
Glucose
45%
Plasma
45%
Oral Glucose Tolerance Test
36%
Insulin Resistance
27%
Gluconeogenesis
27%
Abdominal Fat
27%
Visceral Fat
27%
Fatty Acid
18%
Diabetes Mellitus
18%
Insulin Sensitivity
18%
Tissues
18%
Patient
18%
Magnetic Resonance Imaging
9%
Body Weight
9%
Hemoglobin A1c
9%
Maturity Onset Diabetes of the Young
9%
Patient with Type 2 Diabetes
9%
Body Mass Index
9%
Sulfonylurea
9%
Insulin Infusion
9%
Diet
9%
Infusion Rate
9%
Tritium
9%
Immunoreactive Insulin
9%
Age
9%
Man
9%
Woman
9%
Inpatient
9%
Adipose Tissue
9%
Agricultural and Biological Sciences
Pioglitazone
100%
Insulin
54%
Glucose Tolerance Test
36%
Area
36%
Glucose
27%
Insulin Resistance
27%
Abdominal Fat
27%
Visceral Fat
27%
Tissues
18%
Body Weight
9%
Body Mass Index
9%
Magnetic Resonance Imaging
9%
Sulfonylurea
9%
Women
9%
Age
9%
Males
9%
Human Nutrition
9%
Pharmacology, Toxicology and Pharmaceutical Science
Pioglitazone
100%
Insulin
63%
Glucose
45%
Fat
45%
Insulin Resistance
27%
Diabetes Mellitus
18%
Fatty Acid
18%
Non Insulin Dependent Diabetes Mellitus
9%
Tritium
9%
Sulfonylurea
9%
Hemoglobin A1c
9%
Immunoreactive Insulin
9%
Biochemistry, Genetics and Molecular Biology
Pioglitazone
100%
Insulin
54%
Glucose
27%
Insulin Resistance
27%
Gluconeogenesis
27%
Glucose Blood Level
18%
Insulin Sensitivity
18%
Body Mass
9%
Insulin Level
9%
Body Weight
9%
Insulin Blood Level
9%
Fat Free Mass
9%
Sulfonylurea
9%
Age
9%
Dose
9%
Fat Mass
9%
Neuroscience
Pioglitazone
100%
Insulin
54%
Glucose
27%
Fat
27%
Fatty Acids
18%
Body Mass Index
9%
Magnetic Resonance Imaging
9%
Diabetes Mellitus
9%
Sulfonylurea
9%
Hemoglobin A1c
9%
Suppression
9%
Immunoreactive Insulin
9%